Abstract
BackgroundRituximab is a chimeric anti-CD20 antibody approved in a few indications apart from oncology (rheumatoid arthritis, polyangiitis and Wegener’s granulomatosis). The French funding system allows the off-label use of rituximab...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have